Additionally, data needed for model development includes clinical features of each individual patient such as age, gender, weight, height and ethnicity of the affected child alongside blood work such as inflammatory markers (e.g. CRP, TNF-α, TGF-β), hematologic parameters (e.g. serum iron and hemoglobin) as well as disease burden scores (e.g. the Birmingham Epidermolysis Bullosa Severity Score, the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa or the Epidermolysis Bullosa Disease Activity and Scarring Index) [78]. This evidence concerns the gene TGFB1 and epidermolysis bullosa.